#ASCO14 - Poster: A randomized double-blind, comparative study of ARN-509 plus androgen deprivation therapy (ADT) vs ADT alone in non-metastatic castration-resistant prostate cancer–the SPARTAN trial

CHICAGO, IL USA (UroToday.com) - Presented by Matthew R. Smith,¹ Glenn Liu,² S. Martin Shreeve,³ Shannon Matheny,³ Antonieta Sosa,³ Thian Kheoh,³ Margaret K. Yu,³ and Eric J. Small⁴ at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

¹Harvard Medical School and Massachusetts General Hospital Cancer Center, Boston, MA USA
²University of Wisconsin Carbone Cancer Center, Madison, WI USA
³Janssen Research & Development, Los Angeles, CA USA
⁴University of California San Francisco, San Francisco, CA USA